Identification of proteins related to brain tumors
The Proteomics research group within the Brain Tumor Center led by Dr. Theo Luider identifies and researches proteins and their relationship to brain tumors. This mainly concerns the identification of proteins in body material, such as tissue and body fluids.
Using advanced techniques, proteins have been found that are specific for brain tumor blood vessels. These proteins are important for pathological diagnostics and we are now investigating whether the proteins found offer possibilities to better reach a brain tumor with medication.
In addition, we are investigating antibodies against tumor tissue. We determine the sequence of the amino acids (building blocks) of an antibody that is specific for a tumor and also occurs in common in patients. These antibodies can be used as a biomarker or as a new tool to detect tumor antigens.
We are also looking for proteins that occur to an increased degree in the blood of brain tumor patients (tumor markers), so that we can monitor the disease process of brain tumors and the effects of therapy. For this we use an extensive biobank that contains cerebrospinal fluid and blood samples from brain tumor patients.
Errors in the genetic material (mutations in the DNA) of brain tumor cells can lead to altered proteins that may have a different function. We detect these mutated proteins in tissue and blood. By understanding the role these mutated proteins play, we may find new therapies against brain tumors.